MR generic application [Regulatives / Guidelines]

posted by vixen – Czechia, 2020-03-23 19:40 (344 d 16:07 ago) – Posting: # 21296
Views: 1,496

Hi Mikkabel,
More details are needed to determine what we are dealing with here:
- presumably it's an application for Europe?
- is it a single or multiple unit formulation?
- what does the reference SmPC say about intake with/without food?
- is accumulation expected?
- do all three strengths meet the general biowaiver criteria per section 4.1.6 of the Guideline on the investigation of bioequivalence?
- is the shape of all three strengths similar?
- which two strengths represent the extremes? consider it separately for each of the factors listed by section 6.6. of EMA MR Guideline.

Are you familiar with Annex IV to the EMA Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms?

Cheers,
vixen

Complete thread:

Activity
 Admin contact
21,361 posts in 4,461 threads, 1,492 registered users;
online 16 (0 registered, 16 guests [including 3 identified bots]).
Forum time: Wednesday 11:47 CET (Europe/Vienna)

The art and science of asking questions
is the source of all knowledge.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5